Comparison of hemoglobin variability between short- and intermediate-acting erythropoiesis-stimulating agents: a retrospective cohort study
Journal of Yeungnam Medical Science · 28.05.2026 · 43 · 36
DOI: 10.12701/jyms.2026.43.36 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Yeungnam Medical Science, online erschienen am 28.05.2026. Verfasst von Da Eun Park und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Research Foundation of Korea, Ministry of Science, ICT and Future Planning, Ministry of Education.
Abstract (Originalsprache)
Background
This study aims to compare the effects of short- and intermediate-acting erythropoiesis-stimulating agents (ESAs) on hemoglobin (Hb) variability in patients undergoing maintenance hemodialysis.
Methods
This retrospective cohort study included 119 patients who were classified into two groups based on ESA type: short-acting ESA (epoetin alfa/beta [EPO], n=48) and intermediate-acting ESA (darbepoetin alfa [DPO], n=71). Hb levels were measured 11 times at 4-week intervals from ESA therapy initiation to 40 weeks of follow-up. This study used established metrics from previous research, including standard deviation (SD), coefficient of variation (CV), and residual SD, to quantify Hb variability.
Results
Over the 40-week study period with 4-week measurement intervals, mean Hb levels were comparable between the two ESA groups. In the EPO and DPO groups, SD was 0.67±0.19 g/dL and 0.69±0.22 g/dL, respectively (p=0.516), CV was 0.06±0.02 and 0.07±0.02, respectively (p=0.480), and residual SD was 0.73±0.21 g/dL and 0.76±0.26 g/dL, respectively (p=0.463). No significant differences in Hb variability were observed between the groups over 40 weeks using SD, CV, and residual SD.
Conclusion
This retrospective cohort study showed comparable mean Hb levels and Hb variability indices between groups. With respect to Hb variability, the findings reveal no clear basis for prioritizing either short-acting or intermediate-acting ESA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
- Division of Nephrology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea. kangkang@ynu.ac.kr.
Förderung
- National Research Foundation of Korea
- Ministry of Science, ICT and Future Planning
- Ministry of Education
Zitieren
APA
Park, D. E., Choi, H. D., Park, Y. E., Kim, K. B., Kim, A. Y., Cho, K. H., Park, J. W., Do, J. Y., & Kang, S. H. (2026). Comparison of hemoglobin variability between short- and intermediate-acting erythropoiesis-stimulating agents: a retrospective cohort study. Journal of Yeungnam Medical Science, 43, 36. https://doi.org/10.12701/jyms.2026.43.36
Vancouver
Park DE, Choi HD, Park YE, Kim KB, Kim AY, Cho KH, et al. Comparison of hemoglobin variability between short- and intermediate-acting erythropoiesis-stimulating agents: a retrospective cohort study. Journal of Yeungnam Medical Science. 2026;43:36. doi:10.12701/jyms.2026.43.36
BibTeX
@article{Park2026,
author = {Park, Da Eun and Choi, Hae Dong and Park, Young Eun and Kim, Ki Baek and Kim, A Young and Cho, Kyu Hyang and Park, Jong Won and Do, Jun Young and Kang, Seok Hui},
title = {Comparison of hemoglobin variability between short- and intermediate-acting erythropoiesis-stimulating agents: a retrospective cohort study},
journal = {Journal of Yeungnam Medical Science},
year = {2026},
volume = {43},
pages = {36},
doi = {10.12701/jyms.2026.43.36}
}
EUVIMED